Literature DB >> 32016052

Prolyl hydroxylase domain inhibitors: a new era in the management of renal anemia.

Yu Kurata1, Tetsuhiro Tanaka1, Masaomi Nangaku1.   

Abstract

Entities:  

Year:  2019        PMID： 32016052      PMCID： PMC6976456          DOI： 10.21037/atm.2019.09.118

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  25 in total

1.  The balance of beneficial and deleterious effects of hypoxia-inducible factor activation by prolyl hydroxylase inhibitor in rat remnant kidney depends on the timing of administration.

Authors:  Xiaofang Yu; Yi Fang; Hong Liu; Jiaming Zhu; Jianzhou Zou; Xunhui Xu; Suhua Jiang; Xiaoqiang Ding
Journal:  Nephrol Dial Transplant       Date:  2012-03-06       Impact factor: 5.992

2.  Correction of anemia with epoetin alfa in chronic kidney disease.

Authors:  Ajay K Singh; Lynda Szczech; Kezhen L Tang; Huiman Barnhart; Shelly Sapp; Marsha Wolfson; Donal Reddan
Journal:  N Engl J Med       Date:  2006-11-16       Impact factor: 91.245

3.  Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH.

Authors:  Eliska Svastová; Alzbeta Hulíková; Monika Rafajová; Miriam Zat'ovicová; Adriana Gibadulinová; Angela Casini; Alessandro Cecchi; Andrea Scozzafava; Claudiu T Supuran; Jaromír Pastorek; Silvia Pastoreková
Journal:  FEBS Lett       Date:  2004-11-19       Impact factor: 4.124

4.  Hypoxia in renal disease with proteinuria and/or glomerular hypertension.

Authors:  Tetsuhiro Tanaka; Toshio Miyata; Reiko Inagi; Toshiro Fujita; Masaomi Nangaku
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

5.  Stable expression of HIF-1alpha in tubular epithelial cells promotes interstitial fibrosis.

Authors:  Kuniko Kimura; Masayuki Iwano; Debra F Higgins; Yukinari Yamaguchi; Kimihiko Nakatani; Koji Harada; Atsushi Kubo; Yasuhiro Akai; Erinn B Rankin; Eric G Neilson; Volker H Haase; Yoshihiko Saito
Journal:  Am J Physiol Renal Physiol       Date:  2008-07-30

Review 6.  Angiogenesis and hypoxia in the kidney.

Authors:  Tetsuhiro Tanaka; Masaomi Nangaku
Journal:  Nat Rev Nephrol       Date:  2013-03-05       Impact factor: 28.314

7.  Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition.

Authors:  Debra F Higgins; Kuniko Kimura; Wanja M Bernhardt; Nikita Shrimanker; Yasuhiro Akai; Bernd Hohenstein; Yoshihiko Saito; Randall S Johnson; Matthias Kretzler; Clemens D Cohen; Kai-Uwe Eckardt; Masayuki Iwano; Volker H Haase
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

8.  Activation of hypoxia-inducible factor attenuates renal injury in rat remnant kidney.

Authors:  Young Rim Song; Sun Jin You; Yun-Mi Lee; Ho Joon Chin; Dong-Wan Chae; Yun Kyu Oh; Kwon Wook Joo; Jin Suk Han; Ki Young Na
Journal:  Nephrol Dial Transplant       Date:  2009-09-08       Impact factor: 5.992

9.  Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis.

Authors:  Nan Chen; Chuanming Hao; Bi-Cheng Liu; Hongli Lin; Caili Wang; Changying Xing; Xinling Liang; Gengru Jiang; Zhengrong Liu; Xuemei Li; Li Zuo; Laimin Luo; Jianqin Wang; Ming-Hui Zhao; Zhihong Liu; Guang-Yan Cai; Li Hao; Robert Leong; Chunrong Wang; Cameron Liu; Thomas Neff; Lynda Szczech; Kin-Hung P Yu
Journal:  N Engl J Med       Date:  2019-07-24       Impact factor: 91.245

Review 10.  Erythropoiesis stimulating agents and reno-protection: a meta-analysis.

Authors:  Steve Elliott; Dianne Tomita; Zoltan Endre
Journal:  BMC Nephrol       Date:  2017-01-11       Impact factor: 2.388
View more
  2 in total

1.  Phase 3 Randomized Study Comparing Vadadustat with Darbepoetin Alfa for Anemia in Japanese Patients with Nondialysis-Dependent CKD.

Authors:  Masaomi Nangaku; Kazuoki Kondo; Yoshimasa Kokado; Kiichiro Ueta; Genki Kaneko; Tsubasa Tandai; Yutaka Kawaguchi; Yasuhiro Komatsu
Journal:  J Am Soc Nephrol       Date:  2021-04-21       Impact factor: 14.978

2.  A phase 3, open-label, single-arm study of vadadustat for anemia in chronic kidney disease for Japanese patients on hemodialysis not receiving erythropoiesis-stimulating agents.

Authors:  Masaomi Nangaku; Kazuoki Kondo; Souichirou Takabe; Kiichiro Ueta; Tsubasa Tandai; Yutaka Kawaguchi; Yasuhiro Komatsu
Journal:  Ther Apher Dial       Date:  2021-06-28       Impact factor: 2.195
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.